Done Global

It's a complex and evolving area, but I can give you the current landscape and recommend some services. Key Regulatory Context (Important to Understand First): DEA Regulations: The Drug Enforcement Administration (DEA) regulates controlled substances. Historically, prescribing controlled medications via telehealth often required an initial in-person visit. COVID-19 Public Health Emergency (PHE) Waiver: During the PHE, the DEA issued waivers that allowed providers to prescribe controlled medications, including stimulants, via telehealth without an initial in-person visit. This greatly expanded access. PHE Expiration & Extensions: The PHE officially ended on May 11, 2023. However, due to public input and the need for more time to develop permanent rules, the DEA has extended the PHE flexibilities through December 31, 2024. This means, for now, online services can continue to prescribe controlled medications like stimulants without a prior in-person visit, provided they comply with all other federal and state laws. Future Changes: Be aware that this is a temporary extension. The DEA is still working on permanent rules, which could change the landscape again in 2025 and beyond. Important Considerations Before Using Online Services for Stimulants: Thorough Evaluation: Any legitimate service will require a comprehensive psychiatric evaluation to diagnose ADHD (or other conditions requiring stimulants) and rule out contraindications. State-Specific Laws: Even with federal waivers, state laws can vary. Ensure the service operates legally in your state. Provider Discretion: Not all providers on these platforms will be comfortable prescribing stimulants via telehealth, especially for new patients. Follow-Up Care: Expect regular follow-up appointments to monitor efficacy, side effects, and adherence. Some providers or states might eventually require an in-person visit after a certain period. Insurance Coverage: Coverage for telehealth and controlled medication prescriptions varies widely by insurance plan. Online Services That May Prescribe Controlled Medications (Stimulants) Here are some online services that have, under the current extended DEA flexibilities, the potential to prescribe controlled medications like stimulants. They typically focus on mental health and ADHD treatment. ADHD Online: Why: Specializes specifically in ADHD diagnosis and treatment. They offer comprehensive evaluations, including a formal diagnosis, and if appropriate, medication management which can include stimulant prescriptions. They pride themselves on adhering to regulatory guidelines. Klarity: Why: Focuses on connecting patients with licensed psychiatric providers for ADHD diagnosis and treatment, including medication management. They often highlight their ability to prescribe controlled substances under the current regulations, following a thorough assessment. Done Global (Done. ADHD): Why: One of the pioneering telehealth platforms specifically for ADHD. They offer diagnosis and medication management, including stimulants. Caveat: Done has faced significant scrutiny and investigations in the past regarding prescribing practices. While they continue to operate, it's crucial to be aware of their history and ensure they are adhering to all current regulations and providing comprehensive care. Cerebral: Why: A broader mental health platform that also offers ADHD diagnosis and medication management. Caveat: Similar to Done, Cerebral has also faced regulatory investigations regarding its prescribing practices for controlled substances. While they've made efforts to improve compliance, it's important to proceed with caution and verify their current practices. Teladoc / Amwell (and other large general telehealth platforms): Why: These are large, established telehealth platforms that offer a wide range of medical and mental health services. While not ADHD-specific, you can often find psychiatrists or psychiatric nurse practitioners on their platforms who specialize in ADHD and are able to prescribe stimulants after a thorough evaluation, in accordance with federal and state laws. You'll need to filter for providers who offer this specific service. Brightside Health: Why: Primarily known for depression and anxiety treatment, Brightside also offers care for ADHD. They have prescribers who can manage stimulant medications if determined appropriate after an assessment. Their model emphasizes integrated care with therapy. Before you choose a service, always: Check their specific policies regarding controlled substance prescriptions in your state. Understand their diagnostic process and what it entails. Verify their providers' credentials and licensing. Ask about their follow-up protocols and what happens if the DEA rules change. It's always a good idea to discuss your options with your primary care physician first, as they might have recommendations or be able to provide referrals. Disclaimer: I am an AI and cannot provide medical advice. This information is for general knowledge and informational purposes only, and does not constitute medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment. The regulatory landscape for controlled medications via telehealth is subject to change.

Mentioned in position 3 of 7

The rules surrounding online ADHD prescriptions, particularly for stimulant medications, are complex and have been in a state of flux. Here's a breakdown of how controlled substance regulations affect them: Why ADHD Medications are Regulated Most effective ADHD medications are stimulants (e.g., Adderall, Ritalin, Vyvanse, Concerta). These are classified as Schedule II controlled substances by the Drug Enforcement Administration (DEA) due to their high potential for abuse and diversion. This classification imposes strict rules: No automatic refills: A new prescription must be issued each month. Specific prescribing requirements: Historically, this meant an in-person visit. State and Federal Oversight: Both federal and state laws govern their prescription. The Pre-COVID Baseline: The Ryan Haight Act (2008) Before the COVID-19 pandemic, the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally required at least one in-person medical evaluation before a doctor could prescribe a controlled substance via telehealth. This meant getting an ADHD stimulant prescription solely online was largely impossible or highly restricted. The COVID-19 Exception: The Public Health Emergency (PHE) Waiver When the COVID-19 Public Health Emergency (PHE) was declared, the DEA issued waivers to the Ryan Haight Act. This allowed healthcare providers to prescribe controlled substances, including stimulant medications for ADHD, via telehealth without an initial in-person medical evaluation. This led to a significant increase in online ADHD clinics and easier access to prescriptions for many. The Post-COVID Transition: What's Happening Now The Public Health Emergency officially ended on May 11, 2023. This triggered a complex transition period for telehealth controlled substance prescribing: Initial DEA Proposal (March 2023): The DEA initially proposed rules that would have largely reverted to the pre-PHE requirements, meaning a mandatory in-person visit for controlled substances after an initial 30-day telehealth prescription. This sparked significant public outcry due to concerns about access to care. Grace Period and Revised Proposal (May 2023 onwards): Due to overwhelming public comment, the DEA extended the telehealth flexibilities. For patients who established a telehealth relationship before* November 11, 2023, and received a controlled substance prescription: They can continue to receive prescriptions via telehealth from their existing provider until November 11, 2024, without an in-person visit. For patients establishing a new telehealth relationship after* November 11, 2023, or existing patients after November 11, 2024: The in-person requirement is expected to return unless new, more permanent rules are implemented. New Permanent Rules: The DEA is still working on final rules for permanent telehealth prescribing of controlled substances. They received over 38,000 public comments and are reviewing these to craft a more balanced approach. The outcome is not yet finalized, but it's likely to involve some form of in-person assessment requirement at some point in the treatment course for Schedule II medications. State-Specific Rules It's crucial to remember that state laws can be stricter than federal laws. Some states may have already imposed, or will impose, their own in-person requirements or limitations on telehealth for controlled substances, regardless of federal guidelines. How This Affects Online ADHD Prescriptions (and Specific Brands) Online ADHD prescription services that boomed during the PHE are now navigating this transitional period: Existing Patients (Grace Period): If you started with an online provider like Done Global (Done ADHD), ADHD Online, or Circle Medical before November 11, 2023*, you should be able to continue receiving your prescriptions via telehealth until November 11, 2024. However, it's vital to confirm directly with your provider about their specific plan and whether they anticipate future in-person requirements or referrals. Why they might be affected: Even within the grace period, some providers may choose to implement stricter policies or require in-person visits sooner due to liability concerns, state laws, or preparation for future regulations. New Patients: If you are seeking a new ADHD diagnosis and prescription now, especially for stimulants, you will likely encounter difficulties getting started purely online. Most reputable online services are preparing for, or already implementing, a requirement for an in-person visit at some point early in the treatment process. What to look for: Some online services may partner with local clinics or have in-person components (e.g., Circle Medical has a hybrid model in some areas where they might offer in-person visits). Others might refer you to local providers. Non-Stimulant Medications: If you're prescribed non-stimulant ADHD medications (e.g., Atomoxetine/Strattera, Guanfacine ER/Intuniv, Viloxazine/Qelbree), these are generally not* controlled substances. Prescribing these via telehealth remains much less restricted and is typically not affected by the Ryan Haight Act or the current DEA rule changes. Why this is easier: These medications don't carry the same abuse potential, so the regulatory scrutiny is lower. Many online platforms can still readily prescribe these. Recommendations for Consumers: If you are an existing patient: Contact your current online provider (e.g., Done Global, ADHD Online, Circle Medical) immediately. Ask them directly about their policy regarding the end of the PHE waivers and their plan for continued controlled substance prescribing after November 11, 2024. Be prepared for an eventual in-person visit. Start researching local psychiatrists or primary care physicians who are accepting new patients and manage ADHD. If you are a new patient seeking an ADHD prescription: Prioritize in-person evaluations: The most reliable way to get a stimulant prescription long-term will likely involve at least one in-person visit. Look for local psychiatrists, neurologists, or even some primary care providers. Consider hybrid models: Some services may offer a combination of online assessment and in-person follow-up, or facilitate referrals to local partners. Discuss non-stimulant options: If access to stimulants is difficult via telehealth, discuss non-stimulant medications with your provider as a potentially more accessible alternative. Verify licenses: Always ensure any telehealth provider is licensed to practice in your specific state. In summary, the era of easy, entirely online stimulant ADHD prescriptions established during the COVID-19 pandemic is drawing to a close. While there's a grace period for many existing patients, the future will likely involve stricter requirements, including eventual in-person evaluations for controlled substances.

Mentioned in position 1 of 3

The rules around controlled substances, including most ADHD medications (like Adderall, Ritalin, Vyvanse), significantly impact online prescribing. It's a complex and rapidly evolving area, particularly since the end of the COVID-19 Public Health Emergency (PHE). Here's a breakdown: The Core Problem: ADHD Meds are Controlled Substances Schedule II Classification: Most stimulant ADHD medications are classified as Schedule II controlled substances by the U.S. Drug Enforcement Administration (DEA). This means they have a high potential for abuse and dependence, leading to strict regulations. Historical In-Person Rule: Historically, federal law required an in-person medical evaluation before a doctor could prescribe a Schedule II controlled substance. This was a major barrier for fully online ADHD treatment. The COVID-19 Public Health Emergency (PHE) Waiver Temporary Relaxation: During the COVID-19 PHE, the DEA issued waivers that temporarily allowed doctors to prescribe controlled substances via telehealth, even if they hadn't seen the patient in person first. This was crucial for maintaining access to care during lockdowns. Boom in Telehealth: This waiver led to a significant increase in telehealth providers offering online ADHD diagnosis and stimulant prescriptions (e.g., Done Global, Cerebral). Post-PHE: The Current (and Evolving) Landscape PHE End: The PHE officially ended on May 11, 2023. This meant the waivers expired. DEA's Temporary Extension (Grace Period): Recognizing the potential disruption, the DEA implemented a temporary extension of the full telehealth flexibilities. For existing patients: If you established a patient-prescriber relationship during the PHE (before May 11, 2023) and were being prescribed a controlled substance via telehealth, you could continue to do so until November 11, 2023. The DEA later extended this again to November 11, 2024, for those who established care by* November 11, 2023. For new patients: If you were seeking a new controlled substance prescription after* May 11, 2023, without an prior in-person visit, the rules generally reverted closer to the pre-PHE requirements, meaning an in-person evaluation was likely needed. New Proposed Rules: The DEA is currently working on new, permanent telehealth rules for controlled substances. They initially proposed rules that would require an in-person visit for an initial prescription of Schedule II medications (or a telehealth visit followed by an in-person visit within 30 days), but these have been met with significant public feedback and are still under review. What This Means for Consumers Seeking Online ADHD Prescriptions: Increased Scrutiny & Difficulty for New Prescriptions: It is much harder to get an initial prescription for stimulant ADHD medication fully online without any prior in-person contact. Many reputable telehealth providers will not initiate stimulant prescriptions without an initial in-person evaluation or a referral from a doctor who has seen you in person. Focus on Follow-Ups: Telehealth is still widely used and accepted for follow-up appointments and refills after an initial in-person evaluation has established the patient-prescriber relationship and prescription. State-Specific Laws: Always remember that individual states can have their own stricter rules regarding telehealth and controlled substances that supersede federal guidelines. Company Changes: Many telehealth companies that relied heavily on the PHE waivers have had to adjust their policies, scale back services, or even face legal issues (e.g., Cerebral and Done Global faced investigations and significantly changed their prescribing practices for stimulants). Recommendations for Navigating Online ADHD Prescriptions: Given the evolving landscape, focus on services that prioritize compliance and comprehensive care: Hybrid Models: Look for services that can facilitate a hybrid approach where an initial in-person visit (either with them directly or via referral from your primary care provider) is followed by online check-ins and refills. Many traditional clinics now offer this. Established Telehealth Providers (with caveats): Teladoc or Amwell: Larger, more established telehealth platforms might offer ADHD diagnosis and treatment, but they often have very strict policies regarding controlled substances, sometimes requiring an in-person referral or declining to prescribe Schedule II meds entirely for initial consultations. They are generally safer bets for general mental health, but for stimulants, you need to verify their specific policy for your state. Local Psychiatric Practices Offering Telehealth: Many local psychiatrists and mental health clinics have expanded their services to include telehealth for established patients. This is often the most compliant and comprehensive route, as they can combine in-person evaluations with convenient online follow-ups. Platforms that Focus on Non-Stimulants or Therapy First: Some platforms will treat ADHD but may lean towards non-stimulant medications (e.g., Strattera, Wellbutrin) or therapy initially, which have fewer controlled substance restrictions. This might be a starting point if you're not solely focused on stimulants. Be Wary of "Easy" Prescriptions: If a service promises immediate stimulant prescriptions with minimal evaluation, it's a red flag. Legitimate providers will conduct thorough assessments, which often involves multiple steps. In summary, while online ADHD prescriptions for controlled substances were widely available during the pandemic, the rules have largely reverted, making initial prescriptions much harder to obtain without an in-person component. For ongoing care, telehealth remains a valuable tool once a patient-prescriber relationship has been properly established. Always verify the latest federal and state regulations and the specific policies of any telehealth provider you consider.

Mentioned in position 1 of 4